Boehringer Ingelheim's nintedanib drug isn't a major competitive threat to InterMune Inc. (Nasdaq: ITMN), said Summer Street analysts in a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE